Journal Article

Misreporting contraceptive use and the association of peak study progestin levels with weight and BMI among women randomized to the progestin-only injectable contraceptives DMPA-IM and NET-EN

Smit, Jenni, Seocharan, Ishen, Batting, Joanne, Chen, Pai-Lien, Hapgood, Janet P., Africander, Donita, Skosana, Salndave B., Beesham, Ivana, Avenant, Chanel, Bick, Alexis J., Singata-Madliki, Mandisa, Balakrishna, Yusentha, Moliki, Johnson Mosoko, Storbeck, Karl-Heinz, Dlamini, Sigcinile, Hofmeyr, G. Justus, Beksinska, Mags

2023

Overview

Progestin-only injectable contraceptives, mainly depo-medroxyprogesterone acetate intramuscular (DMPA-IM), are the most widely used contraceptive methods in sub-Saharan Africa. Insufficient robust data on their relative side-effects and serum concentrations limit understanding of reported outcomes in contraception trials. The WHICH clinical trial randomized HIV-negative women to DMPA-IM (n = 262) or norethisterone enanthate (NET-EN) (n = 259) at two South African sites between 2018–2019. We measured serum concentrations of study and non-study progestins at initiation (D0) and peak serum levels, one week after the 24-week injection [25 weeks (25W)], (n = 435) and investigated associations between study progestin levels, and BMI and weight of participants. Peak median serum concentrations were 6.59 (IQR 4.80; 8.70) nM for medroxyprogesterone (MPA) (n = 161) and 13.6 (IQR 9.01; 19.0) nM for norethisterone (NET) (n = 155). MPA was the most commonly quantifiable non-study progestin at D0 in both arms (54%) and at 25W in the NET-EN arm (27%), followed by NET at D0 in both arms (29%) and at 25W in the DMPA-IM arm (19%). Levonorgestrel was quantifiable in both arms [D0 (6.9%); 25W (3.4%)], while other progestins were quantifiable in ≤ 14 participants. Significant negative time-varying associations were detected between MPA and NET concentrations and weight and BMI in both contraceptive arms and a significant increase was detected for peak serum progestin concentrations for normal weight versus obese women. Contraceptive-related reported outcomes are likely confounded by MPA, more so than NET, with reported DMPA-IM effects likely underestimated, at sites where DMPA-IM is widely used, due to misreporting of contraceptive use before and during trials, and ‘tail’ effects of DMPA-IM use more than six months before trial enrolment. Peak serum levels of MPA and NET are negatively associated with BMI and weight, suggesting another source of variability between trial outcomes and a potential increase in side-effects for normal weight versus overweight and obese women. Trail registration: The clinical trial was registered with the Pan African Clinical Trials Registry (PACTR 202009758229976 ).

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Acetic acid / Birth control / Body Mass Index / Body weight / Chromatography / Clinical trials / Contraception / Contraceptive Agents / Contraceptive drugs / Contraceptives / Demographics / Drug dosages / Evaluation / Family planning / Female / Health aspects / Health sciences / HIV / Human immunodeficiency virus / Humans / Information sharing / Mass spectrometry / Medroxyprogesterone acetate / Medroxyprogesterone Acetate - adverse effects / Methods / Norethindrone - pharmacology / Obesity / Overweight / Pan-Africanism / Progestational hormones / Progestin / Progestins / Research ethics / Scientific imaging / Serum levels / Side effects / Steroids / Transplants & implants / Weight / Women